Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist’s Perspective
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Interleukin (IL) 33, a member of the IL-1 superfamily, is an “alarmin” protein and is secreted in its active form from damaged cells undergoing necrotic cell death. Mast cells are one of the main effector cell types in allergic disorders. They secrete a variety of mediators, including T helper 2 cytokines. As mast cells have high-affinity IgE receptors (FcεRI) on their surface, they can capture circulating IgE. IgE-bound mast cells degranulate large amounts of histamine, heparin, and proteases when they encounter antigens. As IL-33 is an important mediator of innate immunity and mast cells play an important role in adaptive immune responses, interactions between the two could link innate and adaptive immunity. IL-33 promotes the adhesion of mast cells to laminin, fibronectin, and vitronectin. IL-33 increases the expression of adhesion molecules, such as intracellular adhesion molecule-1 and vascular cell adhesion molecule-1, in endothelial cells, thus enhancing mast cell adhesion to blood vessel walls. IL-33 stimulates mast cell proliferation by activating the ST2/Myd88 pathway; increases mast cell survival by the activation of survival proteins such as Bcl-XL; and promotes the growth, development, and maturation of mast cell progenitors. IL-33 is also involved in the activation of mature mast cells and production of different proinflammatory cytokines. The interaction of IL-33 and mast cells could have important clinical implications in the field of clinical urology. Epithelial dysfunction and mast cells could play an important role in the pathogenesis of interstitial cystitis. Urinary levels of IL-33 significantly increase in patients with interstitial cystitis. In addition, the number of mast cells significantly increase in the urinary bladders of patients with interstitial cystitis. Therefore, inhibition of mast cell activation and degranulation in response to increase in IL-33 is a potential therapeutic target in the treatment of interstitial cystitis.
Abstract
Interleukin (IL) 33, a member of the IL-1 superfamily, is an “alarmin” protein and is secreted in its active form from damaged cells undergoing necrotic cell death. Mast cells are one of the main effector cell types in allergic disorders. They secrete a variety of mediators, including T helper 2 cytokines. As mast cells have high-affinity IgE receptors (FcεRI) on their surface, they can capture circulating IgE. IgE-bound mast cells degranulate large amounts of histamine, heparin, and proteases when they encounter antigens. As IL-33 is an important mediator of innate immunity and mast cells play an important role in adaptive immune responses, interactions between the two could link innate and adaptive immunity. IL-33 promotes the adhesion of mast cells to laminin, fibronectin, and vitronectin. IL-33 increases the expression of adhesion molecules, such as intracellular adhesion molecule-1 and vascular cell adhesion molecule-1, in endothelial cells, thus enhancing mast cell adhesion to blood vessel walls. IL-33 stimulates mast cell proliferation by activating the ST2/Myd88 pathway; increases mast cell survival by the activation of survival proteins such as Bcl-XL; and promotes the growth, development, and maturation of mast cell progenitors. IL-33 is also involved in the activation of mature mast cells and production of different proinflammatory cytokines. The interaction of IL-33 and mast cells could have important clinical implications in the field of clinical urology. Epithelial dysfunction and mast cells could play an important role in the pathogenesis of interstitial cystitis. Urinary levels of IL-33 significantly increase in patients with interstitial cystitis. In addition, the number of mast cells significantly increase in the urinary bladders of patients with interstitial cystitis. Therefore, inhibition of mast cell activation and degranulation in response to increase in IL-33 is a potential therapeutic target in the treatment of interstitial cystitis.
참고문헌 (100)
- Kurowska-Stolarska M, "Interleukin- 33: a novel mediator with a role in distinct disease pathologies", J Intern Med, 269, pp.29~35 (2011)
- Cayrol C, "The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1", Proc Natl Acad Sci U S A, 106, pp.9021~9026 (2009)
- Luthi AU, "Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases", Immunity, 31, pp.84~98 (2009)
- Moussion C, "The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’", PLoS One, 3, pp.e3331~ (2008)
- Tago K, "Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V", Biochem Biophys Res Commun, 285, pp.1377~1383 (2001)
- Schmitz J, "IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines", Immunity, 23, pp.479~490 (2005)
- Ho LH, "IL- 33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals", J Leukoc Biol, 82, pp.1481~1490 (2007)
- Kondo Y, "Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system", Int Immunol, 20, pp.791~800 (2008)
- Smithgall MD, "IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells", Int Immunol, 20, pp.1019~1030 (2008)
- Smith DE, "IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma", Clin Exp Allergy, 40, pp.200~208 (2010)
- Matsuba-Kitamura S, "Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis", Int Immunol, 22, pp.479~489 (2010)
- Pushparaj PN, "The cytokine interleukin-33 mediates anaphylactic shock", Proc Natl Acad Sci U S A, 106, pp.9773~9778 (2009)
- Iikura M, "IL-33 can promote survival, adhesion and cytokine production in human mast cells", Lab Invest, 87, pp.971~978 (2007)
- Heger K, "A20-deficient mast cells exacerbate inflammatory responses in vivo", PLoS Biol, 12, pp.e1001762~ (2014)
- Abraham SN, "Mast cell-orchestrated immunity to pathogens", Nat Rev Immunol, 10, pp.440~452 (2010)
- Kalesnikoff J, "New developments in mast cell biology", Nat Immunol, 9, pp.1215~1223 (2008)
- Sayed BA, "The master switch: the role of mast cells in autoimmunity and tolerance", Annu Rev Immunol, 26, pp.705~739 (2008)
- Haenuki Y, "A critical role of IL-33 in experimental allergic rhinitis", J Allergy Clin Immunol, 130, pp.184~194.e11 (2012)
- Belpinati F, "Association of childhood allergic asthma with markers flanking the IL33 gene in Italian families", J Allergy Clin Immunol, 128, pp.667~668 (2011)
- Bonnelykke K, "A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations", Nat Genet, 46, pp.51~55 (2014)
- Ferreira MA, "Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype", J Allergy Clin Immunol, 133, pp.1564~1571 (2014)
- Gudbjartsson DF, "Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction", Nat Genet, 41, pp.342~347 (2009)
- Hirota T, "Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population", Nat Genet, 44, pp.1222~1226 (2012)
- Hunninghake GM, "TSLP polymorphisms are associated with asthma in a sex-specific fashion", Allergy, 65, pp.1566~1575 (2010)
- Li J, "Discovering susceptibility genes for allergic rhinitis and allergy using a genome-wide association study strategy", Curr Opin Allergy Clin Immunol, 15, pp.33~40 (2015)
- Moffatt MF, "A large-scale, consortium-based genomewide association study of asthma", N Engl J Med, 363, pp.1211~1221 (2010)
- Ramasamy A, "Genome-wide association studies of asthma in population-based cohorts confirm known and suggested loci and identify an additional association near HLA", PLoS One, 7, pp.e44008~ (2012)
- Savenije OE, "Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood", J Allergy Clin Immunol, 134, pp.170~177 (2014)
- Shimizu M, "Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis", Hum Mol Genet, 14, pp.2919~2927 (2005)
- Torgerson DG, "Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations", Nat Genet, 43, pp.887~892 (2011)
- Prefontaine D, "Increased IL-33 expression by epithelial cells in bronchial asthma", J Allergy Clin Immunol, 125, pp.752~754 (2010)
- Asaka D, "Elevated levels of interleukin-33 in the nasal secretions of patients with allergic rhinitis", Int Arch Allergy Immunol, 158(Suppl 1), pp.47~50 (2012)
- Gluck J, "Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity", Inflamm Res, 61, pp.547~550 (2012)
- Savinko T, "IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors", J Invest Dermatol, 132, pp.1392~1400 (2012)
- Tamagawa-Mineoka R, "Increased serum levels of interleukin 33 in patients with atopic dermatitis", J Am Acad Dermatol, 70, pp.882~888 (2014)
- Hueber AJ, "IL-33 induces skin inflammation with mast cell and neutrophil activation", Eur J Immunol, 41, pp.2229~2237 (2011)
- Duan L, "The role of IL-33 in rheumatic diseases", Clin Dev Immunol, 2013, pp.924363~ (2013)
- Nabe T, "Interleukin (IL)-33: new therapeutic target for atopic diseases", J Pharmacol Sci, 126, pp.85~91 (2014)
- Wang S, "IL-33: a potential therapeutic target in autoimmune diseases", J Investig Med, 60, pp.1151~1156 (2012)
- Lohning M, "T1", ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function, 1998, pp.95, 6930~6935
- Qiu C, "Anti-interleukin- 33 inhibits cigarette smoke-induced lung inflammation in mice", Immunology, 138, pp.76~82 (2013)
- Lee HY, "Blockade of IL-33", ST2 ameliorates airway inflammation in a murine model of allergic asthma, 2014, pp.40, 66~76
- Kakkar R, "The IL-33", ST2 pathway: therapeutic target and novel biomarker, 2008, pp.7, 827~840
- McLean MH, "Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti- TNF therapy", Inflamm Bowel Dis, 20, pp.389~397 (2014)
- Oboki K, "IL- 33 is a crucial amplifier of innate rather than acquired immunity", Proc Natl Acad Sci U S A, 107, pp.18581~18586 (2010)
- Liu X, "IL-33", ST2 pathway contributes to metastasis of human colorectal cancer, 2014, pp.453, 486~492
- Yu XX, "IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1", 2 Pathway, 2015, pp.60, 1265~1272
- Villarreal DO, "Interleukin 33: a switch-hitting cytokine", Curr Opin Immunol, 28, pp.102~106 (2014)
- Pomeshchik Y, "Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury", Brain Behav Immun, 44, pp.68~81 (2015)
- Barbour M, "IL- 33 attenuates the development of experimental autoimmune uveitis", Eur J Immunol, 44, pp.3320~3329 (2014)
- "IL-33 and Thymic Stromal Lymphopoietin in mast cell functions" (2015)[URL]
- Motakis E, "Redefinition of the human mast cell transcriptome by deep-CAGE sequencing", Blood, 123, pp.e58~e67 (2014)
- Dastych J, "Stem cell factor induces mast cell adhesion to fibronectin", J Immunol, 152, pp.213~219 (1994)
- Choi YS, "Nuclear IL- 33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation", Biochem Biophys Res Commun, 421, pp.305~311 (2012)
- Saluja R, "Interleukin-33 promotes the proliferation of mouse mast cells through ST2", MyD88 and p38 MAPK-dependent and Kit-independent pathways, 2014, pp.28, 575~585
- Wang JX, "IL-33", ST2 axis promotes mast cell survival via BCLXL, 2014, pp.111, 10281~10286
- Allakhverdi Z, "Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells", J Immunol, 179, pp.2051~2054 (2007)
- Enoksson M, "Mast cells as sensors of cell injury through IL-33 recognition", J Immunol, 186, pp.2523~2528 (2011)
- Moulin D, "Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells", Cytokine, 40, pp.216~225 (2007)
- Xu D, "IL-33 exacerbates autoantibody-induced arthritis", J Immunol, 184, pp.2620~2626 (2010)
- Eklund KK, "Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy", Immunol Rev, 217, pp.38~52 (2007)
- Enoksson M, "Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent", Blood, 121, pp.530~536 (2013)
- Komai-Koma M, "Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice", Allergy, 67, pp.1118~1126 (2012)
- Talabot-Ayer D, "Interleukin-33 is biologically active independently of caspase-1 cleavage", J Biol Chem, 284, pp.19420~19426 (2009)
- Silver MR, "IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation", Inflamm Res, 59, pp.207~218 (2010)
- Andrade MV, "Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33", Eur J Immunol, 41, pp.760~772 (2011)
- Jung MY, "IL-33 induces a hyporesponsive phenotype in human and mouse mast cells", J Immunol, 190, pp.531~538 (2013)
- Chu Y, "B cells lacking the tumor suppressor TNFAIP3", A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice, 2011, pp.117, 2227~2236
- Hammer GE, "Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis", Nat Immunol, 12, pp.1184~1193 (2011)
- Kool M, "The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity", Immunity, 35, pp.82~96 (2011)
- Matmati M, "A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis", Nat Genet, 43, pp.908~912 (2011)
- Tavares RM, "The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity", Immunity, 33, pp.181~191 (2010)
- Vereecke L, "Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis", J Exp Med, 207, pp.1513~1523 (2010)
- Ma A, "A20: linking a complex regulator of ubiquitylation to immunity and human disease", Nat Rev Immunol, 12, pp.774~785 (2012)
- Palmer G, "Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis", Arthritis Rheum, 60, pp.738~749 (2009)
- Xu D, "IL-33 exacerbates antigen-induced arthritis by activating mast cells", Proc Natl Acad Sci U S A, 105, pp.10913~10918 (2008)
- Kiss A, "A new mechanism regulating the initiation of allergic airway inflammation", J Allergy Clin Immunol, 120, pp.334~342 (2007)
- Morita H, "An Interleukin-33-Mast Cell-Interleukin-2 Axis Suppresses Papain- Induced Allergic Inflammation by Promoting Regulatory T Cell Numbers", Immunity, 43, pp.175~186 (2015)
- Theoharides TC, "Mast cell involvement in interstitial cystitis: a review of human and experimental evidence", Urology, 57(6 Suppl 1), pp.47~55 (2001)
- 김아람, "Pretreatment Features to Influence Effectiveness of Intravesical Hyaluronic Acid Instillation in Refractory Interstitial Cystitis", Painful Bladder Syndrome, 2014, pp.18(3), 163~167[DOI]
- Kochiashvili G, "Urinary IL-33 and galectin-3 increase in patients with interstitial cystitis", bladder pain syndrome (review), 2014, pp.(232-233), 12~15
- Sant GR, "The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis", Urology, 69(4 Suppl), pp.34~40 (2007)
- Sant GR, "The role of the mast cell in interstitial cystitis", Urol Clin North Am, 21, pp.41~53 (1994)
- Simmons JL, "On the use of an antihistamine in the treatment of interstitial cystitis", Am Surg, 24, pp.664~667 (1958)
- Choi BH, "Mast cell activation and response to tolterodine in the rat urinary bladder in a chronic model of intravesical protamine sulfate and bacterial endotoxin-induced cystitis", Mol Med Rep, 10, pp.670~676 (2014)
- Larsen S, "Mast cells in interstitial cystitis", Br J Urol, 54, pp.283~286 (1982)
- Feltis JT, "Increased mast cells of the bladder in suspected cases of interstitial cystitis: a possible disease marker", J Urol, 138, pp.42~43 (1987)
- Aldenborg F, "Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis", Immunology, 58, pp.411~416 (1986)
- Lynes WL, "Mast cell involvement in interstitial cystitis", J Urol, 138, pp.746~752 (1987)
- Johansson SL, "Clinical features and spectrum of light microscopic changes in interstitial cystitis", J Urol, 143, pp.1118~1124 (1990)
- Enerback L, "Histamine and mucosal mast cells in interstitial cystitis", Agents Actions, 27, pp.113~116 (1989)
- Bullock AD, "Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis", J Urol, 148, pp.1951~1956 (1992)
- Christensen MM, "A guinea pig model for study of bladder mast cell function: histamine release and smooth muscle contraction", J Urol, 144, pp.1293~1300 (1990)
- Ahluwalia A, "Ovalbumin-induced neurogenic inflammation in the bladder of sensitized rats", Br J Pharmacol, 124, pp.190~196 (1998)
- Bjorling DE, "Mast cells mediate the severity of experimental cystitis in mice", J Urol, 162, pp.231~236 (1999)
- Alexacos N, "Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress", Urology, 53, pp.1035~1040 (1999)
- Spanos C, "Stress-induced bladder mast cell activation: implications for interstitial cystitis", J Urol, 157, pp.669~672 (1997)
- Minogiannis P, "Hydroxyzine inhibits neurogenic bladder mast cell activation", Int J Immunopharmacol, 20, pp.553~563 (1998)
- Nurmatov UB, "H1 -antihistamines for primary mast cell activation syndromes: a systematic review", Allergy, 70, pp.1052~1061 (2015)
- 권종규, "Pain, Catastrophizing, and Depression in Chronic Prostatitis", Chronic Pelvic Pain Syndrome, 2013, pp.17(2), 48~58[DOI]